JP2024533485A5 - - Google Patents
Info
- Publication number
- JP2024533485A5 JP2024533485A5 JP2024516380A JP2024516380A JP2024533485A5 JP 2024533485 A5 JP2024533485 A5 JP 2024533485A5 JP 2024516380 A JP2024516380 A JP 2024516380A JP 2024516380 A JP2024516380 A JP 2024516380A JP 2024533485 A5 JP2024533485 A5 JP 2024533485A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- cdr
- self
- ferritin
- differs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163243372P | 2021-09-13 | 2021-09-13 | |
| US63/243,372 | 2021-09-13 | ||
| PCT/CA2022/051361 WO2023035084A1 (en) | 2021-09-13 | 2022-09-13 | Dr5-targeting multabodies for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024533485A JP2024533485A (ja) | 2024-09-12 |
| JP2024533485A5 true JP2024533485A5 (enExample) | 2025-09-22 |
Family
ID=85507784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024516380A Pending JP2024533485A (ja) | 2021-09-13 | 2022-09-13 | がんの治療のためのＤＲ５標的化Ｍｕｌｔａｂｏｄｙ |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240409652A1 (enExample) |
| EP (1) | EP4401790A4 (enExample) |
| JP (1) | JP2024533485A (enExample) |
| KR (1) | KR20240101550A9 (enExample) |
| CN (1) | CN118317980A (enExample) |
| AU (1) | AU2022344813A1 (enExample) |
| CA (1) | CA3231176A1 (enExample) |
| MX (1) | MX2024003139A (enExample) |
| WO (1) | WO2023035084A1 (enExample) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2569336A1 (en) * | 2010-05-14 | 2013-03-20 | Amgen Inc. | Enhanced death receptor agonists |
| KR20190105752A (ko) * | 2018-03-06 | 2019-09-18 | 한국과학기술연구원 | 신규 항암 융합단백질 및 그의 용도 |
| CA3143034A1 (en) * | 2019-06-14 | 2020-12-17 | Cugene Inc. | Novel interleukin-2 variants for the treatment of cancer |
| CA3149320A1 (en) * | 2019-08-01 | 2021-02-04 | The Hospital For Sick Children | Multi-valent and multi-specific nanoparticle platforms and methods |
| TW202600603A (zh) * | 2019-10-24 | 2026-01-01 | 美商普羅米修斯生物科學股份有限公司 | 針對類-tnf配體1a (tl1a)之人類化抗體及其用途 |
| CN115768794A (zh) * | 2020-02-24 | 2023-03-07 | 艾利妥 | 抗trem2抗体的使用方法 |
| JP2023550191A (ja) * | 2020-11-25 | 2023-11-30 | ザ・ホスピタル・フォー・シック・チルドレン | Ｄｒ４および／またはｄｒ５を標的とするポリペプチドならびに関連する組成物および方法 |
-
2022
- 2022-09-13 MX MX2024003139A patent/MX2024003139A/es unknown
- 2022-09-13 JP JP2024516380A patent/JP2024533485A/ja active Pending
- 2022-09-13 WO PCT/CA2022/051361 patent/WO2023035084A1/en not_active Ceased
- 2022-09-13 CA CA3231176A patent/CA3231176A1/en active Pending
- 2022-09-13 AU AU2022344813A patent/AU2022344813A1/en active Pending
- 2022-09-13 CN CN202280062080.6A patent/CN118317980A/zh active Pending
- 2022-09-13 KR KR1020247011876A patent/KR20240101550A9/ko active Pending
- 2022-09-13 EP EP22868435.3A patent/EP4401790A4/en active Pending
- 2022-09-13 US US18/691,258 patent/US20240409652A1/en active Pending